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Introduction
Insulin exerts effects on cells via a widely ramifying signaling network, critically involving phosphory-
lation of  insulin receptor substrate (IRS) proteins by activated insulin receptor, recruitment of  class 1A 
PI3K to the phosphorylated IRS proteins, and thus activation of  the AKT serine threonine kinases by 2 
phosphoinositide-dependent kinases (PDK1 and -2) (1). This signaling cascade culminates in stimulation 
of  glucose uptake by skeletal muscle and adipose tissue, suppression of  hepatic gluconeogenesis, and 
stimulation of  hepatic lipogenesis among other responses.
Obesity-related insulin resistance is associated with fatty liver, dyslipidemia, and low plasma 
adiponectin. Insulin resistance due to insulin receptor (INSR) dysfunction is associated with none 
of these, but when due to dysfunction of the downstream kinase AKT2 phenocopies obesity-
related insulin resistance. We report 5 patients with SHORT syndrome and C-terminal mutations 
in PIK3R1, encoding the p85α/p55α/p50α subunits of PI3K, which act between INSR and AKT 
in insulin signaling. Four of 5 patients had extreme insulin resistance without dyslipidemia 
or hepatic steatosis. In 3 of these 4, plasma adiponectin was preserved, as in insulin receptor 
dysfunction. The fourth patient and her healthy mother had low plasma adiponectin associated 
with a potentially novel mutation, p.Asp231Ala, in adiponectin itself. Cells studied from one patient 
with the p.Tyr657X PIK3R1 mutation expressed abundant truncated PIK3R1 products and showed 
severely reduced insulin-stimulated association of mutant but not WT p85α with IRS1, but normal 
downstream signaling. In 3T3-L1 preadipocytes, mutant p85α overexpression attenuated insulin-
induced AKT phosphorylation and adipocyte differentiation. Thus, PIK3R1 C-terminal mutations 
impair insulin signaling only in some cellular contexts and produce a subphenotype of insulin 
resistance resembling INSR dysfunction but unlike AKT2 dysfunction, implicating PI3K in the 
pathogenesis of key components of the metabolic syndrome.
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Attenuation of  insulin’s glucose-lowering action in vivo, 
termed “insulin resistance,” commonly develops as a mal-
adaptive response to obesity and is widely viewed as a critical 
mediator of  the link between obesity and pandemic disorders, 
including type 2 diabetes, fatty liver, dyslipidemia, subfertility, 
and cancer. However, focusing exclusively on insulin resistance 
while neglecting to consider whether the manifold actions of  
insulin on other aspects of  metabolism and cell growth are 
commensurately impaired is potentially misleading. The tight 
negative feedback loop coupling blood glucose concentration 
to insulin secretion means that the glucose-lowering action of  
insulin determines blood insulin concentration. Defects limit-
ed to this glucose-lowering action thus produce compensatory 
hyperinsulinemia, exposing any less-resistant insulin-respon-
sive pathways or tissues to high levels of  insulin action.
The concept that such “partial” insulin resistance is 
involved in the pathogenesis of  insulin resistance–related dis-
ease has been discussed since at least the 1980s, when it was 
invoked to account theoretically for the association between 
hypertension and insulin resistance (2). Direct experimental 
evidence for the phenomenon was provided in type 2 diabetes and obesity in ensuing years (3–6). Further 
murine studies have since produced data consistent with this general concept (7), which is particularly well 
developed in the case of  insulin action on endothelial cell function (8).
More recently, studies of  humans with single gene disorders of  proximal insulin signaling have sup-
ported the importance of  partial insulin resistance: genetic defects in the insulin receptor, although replicat-
ing in severe form many features of  common insulin resistance (hyperglycemia, extreme hyperinsulinemia, 
ovulatory dysfunction, hyperandrogenism, acanthosis nigricans, and soft tissue overgrowth), do not feature 
other critical components of  the syndrome (elevated plasma triglycerides, suppressed HDL cholesterol, 
fatty liver [refs. 9, 10], and suppressed plasma adiponectin [ref. 11]). In contrast, in a single family with a 
loss-of-function mutation in the serine threonine kinase AKT2, a critical more distal component in insulin 
signaling, affected patients had a severe phenocopy of  the prevalent metabolic syndrome, encompassing 
severe fatty liver, dyslipidemia, and suppressed plasma adiponectin (9). It is not clear at present whether the 
preserved or increased plasma adiponectin seen in insulin receptor dysfunction may play a role in the pro-
tection from fatty liver and dyslipidemia in that state. The metabolic consequences in humans of  primary 
genetic defects in class 1A PI3K, which lies between the insulin receptor and AKT2 in the insulin signaling 
pathway, have not been evaluated in similar detail.
Class 1A PI3K is a heterodimer of  one of  3 p110 catalytic subunits — p110α, p110β and p110δ 
— and one of  5 regulatory subunits, three of  which, namely p85α, p55α, and p50α, are splice vari-
ants derived from the PIK3R1 gene (12). Regulatory subunits harbor 2 phosphotyrosine-binding SH2 
domains and thus play a critical role in PI3K recruitment to phosphorylated receptor tyrosine kinases 
(RTKs) or IRS proteins. Pharmacological studies have implicated p110α most strongly in insulin action 
in adipocytes, with p110β suggested to play a lesser, accessory role (13). In keeping with this, although 
total knockout of  either p110α (14) or p110β (15) is embryonically lethal, heterozygous knockin of  a 
kinase-dead p110α allele (16), or liver-specific ablation of  p110β (17), produces insulin resistance in ear-
ly life. In contrast, knockout of  either p85α (18) or p85β (19) produces a phenotype of  increased insulin 
sensitivity, while knockout of  p85α, p55α, and p50α together is lethal (20). Collectively these studies 
Figure 1. Appearance of patients with severe insulin resistance and 
mutations in PIK3R1. (A) Facial appearance of Patient 1 (P1) at 16 
years old. (B) Posterior view of P1 showing absence of lipodystrophy. 
(C) Facial appearance of P2 aged 13 years old. (D) Composite posteri-
or view of P2 showing lean build with generalized paucity of adipose 
tissue. (E) Facial view of P3 at 13 years old. (F) Posterior view of P3 
showing lean build with generalized paucity of adipose tissue.
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argue for a critical role for PI3K generally in insulin action, but suggest that the role of  the regulatory 
subunits in particular is more complex.
Activating mutations in PIK3R1 have been described in cancers and, more recently, in an immunodefi-
ciency syndrome featuring severely reduced plasma immunoglobulin levels (21, 22). A single patient with 
selective genetic loss of  the p85α isoform has also been described with agammaglobulinemia (23); how-
ever, no systemic metabolic defects have been reported in these disorders. In 2013, mutations in PIK3R1 
were also demonstrated to cause SHORT syndrome, denoting short stature, joint hyperextensibility, ocular 
depression, Rieger anomaly (a developmental defect in the iris), and teething delay (24–26). Lipodystrophy 
is also reported to be common in SHORT syndrome, while insulin resistance has been reported in many, 
though not all, cases (27). Limited studies of  insulin action in patient-derived cells has yielded inconsistent 
findings, though these were interpreted as indicative of  cellular insulin resistance (24–26).
In this report we describe the more detailed metabolic and cellular phenotype of  5 patients with patho-
genic C-terminal PIK3R1 mutations, one of  whom had an additional rare missense mutation, p.Asp231Ala, 
in the ADIPOQ gene and severely suppressed plasma adiponectin concentration.
Table 1. Clinical and biochemical characteristics of 5 patients (P1–P5) harboring mutations in PIK3R1
P1 F1 M1 P2 P3 P4 P5 NR
Age (yr) 16 49 47 14 12 14 9 –
Sex F M F F F F M –
Ethnicity BlackA BlackA BlackA European 
descent
European 
descent
European 
descent
European 
descent
–
PIK3R1 
genotype
Y657X/WT WT/WT WT/WT R649W/WT R649W/WT R649W/WT R649W/WT –
Birth weight, g 
(SDS)
2,540 (–2.4) – – 2,330 (–1.6) 2,020 (–3.3) 2,310 1,860 (–3.7) –
Height, m (SDS) 1.56 (-1.1) 1.88 1.77 1.50 (–1.1) 1.44 (–1.2) 1.57 (–0.1) 1.13B (–0.08) –
Weight, kg 
(SDS)
45.2 (–1.5) 122.9 98.0 33.3 (–2.3) 28.7 (–2.3) 39.8 (–1.1) 15.0B (–3.1) –
BMI, kg/m2 
(SDS)
18.6 (–0.8) 34.4 31.3 14.8 (–2.3) 13.8 (–2.7) 16.1 (–1.5) 11.7B (–4.2) –
HbA1c, mmol/
mol
40 41 38 34 34 44 – 20–41
Glucose, 
mmol/l
Fasting 4.0 6.0 5.1 4.4 4.2 4.9 4.4 <6.1
60 min 12.1 13.4 7.2 NA 8.5 13.2 – –
120 min 11.7 9.6 6.3 NA 10.7 9.2 – –
Insulin, pmol/l
Fasting 150 101 51 921 617 433 183C <60
60 min 4,000 440 411 NA >7,000 6,019– –
120 min 6,460 355 332 NA >7,000 >7,000 – –
Adiponectin, 
mg/l
0.9 (4.4–17.7) 2.8 (2.8–9.9) 0.9 (2.6–14.9) 11.7 (4.4–17.7) 10.0 (4.4–17.7) 10.3 (4.4–17.7) 6.1 (2.6–12.6) D
Leptin, μg/l 10 (2.4–24.4) 10.9 (4.2–26.0) 33.8 (14.9–60.2) 2.5 (2.4–24.4) 4.5 (2.4–24.4) 3.9 (2.4–24.4) 1.6 (0.4–8.3) D
SHBG, nmol/l 101 20 33 24 – – – 18–114
Testosterone, 
nmol/l
5.9 – 1.0 8.4 4.5 3.5 – <2.0 (F)
Triglycerides, 
mmol/l
0.73 1.2 0.9 0.5 0.8 1.1 2.2C <1.7
HDL 
cholesterol, 
mmol/l
1.99 1.4 1.42 1.35 1.4 48.5 1.08 >1.0
ALT (U/l) 9 46 19 13 15 (<31) 27 (<30) 21 9–52
M1 and F1 are the mother and father of P1, respectively. AP1, M1, and F1 are of Yoruba ancestry. BMeasurements at 6.2 years old. C2–3 hours postprandial 
sample. NR, normal range; SDS, standard deviation score. DSex- and BMI-specific reference ranges for leptin and adiponectin are indicated for each patient in 
brackets. SHBG, sex hormone–binding globulin. 
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Results
A syndrome of  normolipidemic insulin resistance without immunodeficiency. The female proband (patient 1 
[P1]) was born to non-consanguineous parents of  Nigerian origin with a birth weight of  2.54 kg at term 
(–2.4 standard deviation scores [SDS]). At 12 years old she presented with symptomatic hyperglycemia 
during a febrile illness. Biochemical evaluation on recovery revealed extreme fasting hyperinsulinemia 
of  1,140 pmol/l but normal fasting glucose. On assessment at 16.2 years, she reported coarse facial hair 
growth and primary amenorrhea but no other symptoms. Mild facial dysmorphism was noted, includ-
ing deep-set eyes, a triangular face with small jaw, and low-set ears (Figure 1A). She was of  short stature 
compared with her parents (height 1.56 m; mid-parental height 1.77 m) and lean (BMI 18.6 kg/m2, SDS 
–0.821) but not lipodystrophic (Figure 1B), with marked flexural acanthosis nigricans, well advanced 
puberty, and mild facial hirsutism. Fasting blood glucose was normal, but diabetes was found after oral 
glucose challenge, with extreme hyperinsulinemia. Fasting serum triglycerides, LDL and HDL cho-
lesterol, and leptin were normal, while plasma adiponectin was extremely low (Table 1). Testosterone 
was severely elevated, and pelvic ultrasound revealed polycystic ovaries. Biochemical indices of  liver 
Figure 2. A de novo heterozygous nonsense mutation in PIK3R1 in a patient with severe insulin resistance. (A) Genomic DNA sequence from patient 1 (P1) 
and her parents showing the de novo p.Tyr657X (Y657X) mutation in PIK3R1. (B) Domain structure of the protein products of PIK3R1 (p85α, p55α, and p50α) 
and predicted truncation site resulting from the nonsense mutation. (C) Full-length and truncated p85α, p55α, and p50α (indicated by arrowheads) and full-
length p85β in EBV-transformed lymphoblastoid cells (EBVLs) from P1 and healthy controls (C1–C4), as assessed by Western blotting for total p85 (p85α/β) 
or p85β alone. (D) Expression of p85α or p85β in dermal fibroblasts from P1 and healthy controls (C1, C2). (E) Quantification of WT and mutant p85α expres-
sion in P1 and control fibroblasts from 4 independent Western blots, normalized to mean expression of WT p85α in controls. *P < 0.05, ***P < 0.005; 1-way 
ANOVA followed by post-hoc Tukey test. Total number of observations indicated in parentheses. Dot plot displays mean ± SEM. (F) Western blot of p110α 
after IP of total p85 in primary dermal fibroblast lysates. (G) Western blot of p110β after IP of total p85 in primary dermal fibroblast lysates.
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function and hepatic ultrasound were normal. Treatment with metformin and a combined cyproterone 
acetate/ethinylestradiol preparation was begun.
Dual-energy X-ray absorptiometry (DXA) revealed a total body fat content of 24.8%, with normal distri-
bution. Proton magnetic resonance spectroscopy (MRS) detected an intrahepatic triglyceride content of 0.1%, 
well below the sex- and ethnicity-matched interquartile range (2.7%–8.9%) for insulin-resistant patients from a 
large, population-based study (28). Intramuscular lipid content was normal. Fasting de novo lipogenesis in the 
liver, assessed by incorporation of deuterium into VLDL, was virtually undetectable at 0.004%. As severe insulin 
resistance without dyslipidemia or fatty liver is characteristic of human insulin receptoropathy, the INSR gene was 
sequenced and found to be normal, and there was no evidence of anti-insulin receptor antibodies on IP assay.
Figure 3. Downstream insulin signaling in patient cells expressing truncated p85α. (A) Western blot of total p85 (p85α/β) in phosphotyrosine immuno-
precipitates or total lysates from dermal fibroblasts from P1 and healthy controls (C1–C3) treated with PBS or 100 nM insulin. Representative blots with 
quantified data from 3 independent experiments normalized to mean baseline intensity (dot plot displays mean ± SEM). Lane order in image of lysate 
blot adjusted to reflect that of the immunoprecipitate blot. (B) Western blot of total p85 (p85α/β) in phospho-IRS1 immunoprecipitates from patient and 
control fibroblasts after treatment with PBS or insulin. Representative blot with quantified data from three independent experiments normalized to mean 
baseline intensity across control cell lines. (C) Phosphatidylinositol-3,4,5-trisphosphate (PIP3) levels in dermal fibroblasts from P1 and healthy controls 
(C1–C5) stimulated with PBS or insulin, as determined by liquid chromatography mass spectroscopy. PIP3 area ratios were normalized to that of an internal 
standard. Dot plot displays median of 2 samples, each quantified in duplicate. Representative of 3 independent experiments. (D) Western blot of phos-
phorylated AKT1/2 (Ser473/474) and ERK1/2 (Thr202/Tyr204) in dermal fibroblasts from P1 and healthy controls (C1, C2) after stimulation with a range of 
insulin doses. Representative blots with quantified data from 3 independent experiments normalized to the highest intensity signal in each experiment 
and a calnexin loading control. Data represent mean ± SEM.
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Both parents were of  normal stature, obese, but without severe insulin resistance. The mother of  the 
proband (M1) also had very low plasma adiponectin concentrations, while the father (F1) had impaired 
fasting glucose and impaired glucose tolerance on glucose challenge (Table 1).
Figure 4. Insulin signaling and adipocyte differentiation in 3T3-L1 preadipocyte models of SHORT syndrome. (A) Total p85 and p110α expression in 
preadipocyte lysates 72 hours after treatment with or without doxycycline (DOX) to induce expression of WT or mutant p85α. β Actin was assessed as 
a loading control. (B) Lipid accumulation, assessed by Oil red O staining on day 10 of an adipocyte differentiation protocol. Doxycycline was added at 
the time points indicated to inducibly overexpress full-length or truncated p85α. (C) Insulin-induced phosphorylation of AKT at Ser473/474 and Thr308 
in preadipocytes infected with WT and mutant p85α lentivirus, with or without doxycycline treatment, after stimulation with 1, 10, or 100 nM insulin 
for 10 minutes. Representative of 3 independent experiments. (D) Quantification of AKT phosphorylation, showing pooled data from 3 independent 
experiments. –DOX and +DOX groups were compared using multiple t tests, with correction for multiple comparisons using the Holm-Šidák method, 
with α = 0.05. Data represent mean ± SEM; *P < 0.05.
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Genetic evaluation of  proband. We hypothesized that the syndrome was caused by either biallelic loss-of-
function mutations (most likely compound heterozygous), or a de novo dominant mutation, in a critical 
insulin signaling–related gene. To address this, we performed exome-wide sequencing of  the proband (P1) 
and her parents and undertook complementary analyses: a search for de novo mutations in the proband 
using DeNovoGear (29) and a search for genes with putative compound heterozygous rare variants. Result-
ing variant lists were filtered to exclude variants unlikely to alter protein function or those common in 
control populations. Three de novo variants but no compound heterozygous variants remained after filter-
ing and validation by Sanger sequencing in the family trio (Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/jci.insight.88766DS1).
Of  the 3 de novo variants, a heterozygous nonsense mutation in PIK3R1, encoding the p85α, p55α, and 
p50α regulatory subunits of  PI3K, stood out. The mutation, p.Tyr657X (Y657X) when numbered accord-
ing to the p85α gene product, was predicted to remove the C-terminal 68 amino acids from all 3 gene prod-
ucts, corresponding to two-thirds of  the C-terminal SH2 domain (Figure 2, A and B). No further variants 
in PIK3R1 were identified, ruling out compound heterozygosity.
Expression and heterodimerization of  mutant PIK3R1. Sequencing of  cDNA from EBV-transformed lym-
phoblastoid cells derived from the proband revealed approximately equal expression of  WT and mutant 
mRNA, with no difference in total PIK3R1 transcript levels, indicating normal expression and stability of  
the mutant mRNA. There was no evidence of  compensatory upregulation of  PIK3R2 or PIK3R3 mRNA, 
encoding the p85β and p55γ regulatory subunits, respectively (Supplemental Figure 1). Immunoblotting 
using an antibody with affinity for all regulatory subunit isoforms showed abundant expression of  trun-
cated p85α protein in addition to full-length protein, while truncated p55α and p50α were also detectable 
(Figure 2C). Immunoblotting of  lysates from dermal fibroblasts with a p85α-specific antibody showed both 
full-length and truncated p85α, while p85β was present only in the WT form, with no evidence of  com-
pensatory upregulation (Figure 2, D and E). In fibroblasts from the proband, the truncated p85α isoform 
was consistently more abundant than its WT counterpart, assessed using both the total p85 antibody and 
the p85α-specific antibody. Moreover, WT p85α was expressed at lower levels in proband cells compared 
with controls (Figure 2, D and E). There was no apparent defect in the capacity of  p110α to dimerize with 
Figure 5. A dominant negative mutation in ADIPOQ. (A) Domain structure of adiponectin, with the approximate site of the p.Asp231Ala (D231A) substi-
tution indicated. SP, signal peptide. (B) Genomic DNA sequence from P1 and her parents showing the D231A mutation in ADIPOQ. (C) Western blot of adi-
ponectin in serum from P1, insulin-resistant controls with mutations in INSR or AKT2, and insulin-sensitive controls (IS), after non-denaturing, non-reduc-
ing SDS-PAGE. Representative of 3 independent experiments. Low- (LMW), medium- (MMW), and high-molecular-weight (HMW) adiponectin complexes 
are indicated. F, female; M, male. (D) Secretion of low-molecular-weight adiponectin complexes into the culture medium of HEK293-T cells transfected 
with 1 μg or 2 μg WT or mutant ADIPOQ or cotransfected with 1 μg WT and 1 μg mutant ADIPOQ, determined by non-denaturing, non-reducing SDS-PAGE, 
followed by Western blotting of adiponectin. Representative blot with quantified data from 3 independent experiments (n = 2 in each experiment), nor-
malized to intensity of the 1 μg WT sample. Dot plot displays mean ± SEM. ***P < 0.005; 1-way ANOVA. EV, empty vector.
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p85, as assessed by IP of  p85 and immunoblotting for p110α in either primary dermal fibroblasts (Figure 
2F) or HEK293-T cells transiently overexpressing HA-tagged p85α and myc-tagged p110α (Supplemental 
Figure 2A). Dimerization with p110β in proband fibroblasts also appeared normal (Figure 2G).
Identification and metabolic phenotyping of  further affected individuals. PIK3R1, PIK3R2, and PIK3CA, encod-
ing the p110α catalytic subunit, were next sequenced in 262 further probands with severe insulin resistance. 
This revealed 3 individuals (P2–P4) all with the same rare missense variant, p.Arg649Trp (R649W), in 
the C-terminal SH2 domain of  PIK3R1. One further patient (P5) was later identified based on syndromic 
features and confirmed also to have the same mutation. (For additional information regarding P2–P5, see 
Supplemental Case Studies.) In all cases, the rare PIK3R1 variant was shown to be de novo on sequencing 
parental DNA. Other rare sequence variants were also discovered in each of  the genes studied; however, 
none of  these were both predicted to be deleterious and cosegregated with severe insulin resistance in the 
families studied, so were not studied further (Supplemental Table 2).
While this study was underway, 3 groups independently reported C-terminal PIK3R1 mutations, includ-
ing both p.Tyr657X and p.Arg649Trp, to be the cause of  SHORT syndrome (24–26). All 5 patients with 
PIK3R1 mutations we describe had facial features in keeping with SHORT syndrome, as well as varying num-
bers of  other previously described features (Supplemental Table 3). Although P1 had no lipodystrophy, P2, 
P3, and P4 had general paucity of  subcutaneous fat, which was more apparent postpubertally (P2 and P3 are 
shown in Figure 1). Although P5 also had sparse subcutaneous adipose tissue, it is difficult to discriminate this 
from healthy leanness in a prepubertal boy. All patients had leptin levels toward the lower end of  the normal 
range (Table 1), consistent with low adipose mass. In all cases, immunoglobulin levels and blood cell counts 
were normal, and no patient had a clinical history suggestive of  immunodeficiency (Supplemental Table 3).
We next assessed whether the 4 additional patients with PIK3R1 mutations shared the insulin resistance 
subphenotype of  the proband. Three of  the 4 additional patients (P2–P4), females between 12 and 14 years 
old at the time of  evaluation, had severe insulin resistance, yet, like P1, they showed no dyslipidemia or 
evidence of  fatty liver (Table 1). Unlike P1, however, they each had strikingly preserved plasma adiponec-
tin levels, with values above the mean for females. This finding, in the context of  severe insulin resistance, 
was previously considered to be pathognomonic of  insulin receptor loss of  function (11, 30, 31). The final 
patient (P5), a prepubertal boy of  9 years old, was evaluated in less detail in the nonfasting state and 
showed neither clinical nor biochemical evidence of  severe insulin resistance or dyslipidemia.
Cellular consequences of  PIK3R1 truncation. Although the N-terminal SH2 domain in PIK3R1 gene prod-
ucts is believed to play the dominant role in phosphotyrosine binding, some studies have suggested that the 
C-terminal domain also plays a significant role (32). In human primary dermal fibroblasts from healthy 
controls, p85 was abundant in phosphotyrosine immunoprecipitates, and this showed a trend toward an 
increase after insulin stimulation (Figure 3A). In contrast, no mutant p85 was detectable in phosphotyro-
sine immunoprecipitates from fibroblasts from P1 either in the basal or insulin-stimulated state, in spite of  
a high level of  expression in the corresponding lysates. No increase in full-length p85 appearance in phos-
photyrosine complexes was seen after insulin stimulation in P1 (Figure 3A). Insulin stimulation did lead to 
the appearance of  p85 in IRS1 immunoprecipitates in control cells, but no mutant p85 could be detected 
in immunoprecipitates from cells from P1. Recruitment of  full-length p85 to IRS1 in response to insulin in 
the same cells was not reduced, however (Figure 3B). Finally, in HEK293-T cells transiently overexpressing 
HA-tagged WT or mutant p85α, together with myc-tagged p110α, less HA-tagged mutant p85 coimmuno-
precipitated with phosphotyrosine than WT HA-p85, and insulin-induced association of  mutant but not 
WT p85 was abolished (Supplemental Figure 2B).
These findings in primary cells and a cell line heterologously expressing p85 suggest that recruitment 
of  the mutant p85 to tyrosine-phosphorylated IRS1 is severely suppressed or absent; however, in primary 
skin cells from the proband, this does not impair recruitment of  coexpressed WT p85. Insulin-induced 
generation of  phosphatidylinositol-3,4,5-trisphosphate (PIP3) and phosphorylation of  the key downstream 
substrate AKT, a PIP3-dependent process, were next assessed in patient cells. The insulin-induced increase 
in PIP3 levels (Figure 3C) and AKT phosphorylation (Figure 3D) showed no difference between patient 
and control dermal fibroblasts, even when the latter was examined in response to a wide range of  different 
insulin doses. There was, however, a nonsignificant increase in basal AKT phosphorylation (Figure 3D). 
Furthermore there was no evidence of  a faster rate of  AKT dephosphorylation after ligand was washed 
off  the cells (Supplemental Figure 3), and both WT and mutant p85α coimmunoprecipitated with the PIP3 
phosphatase PTEN (Supplemental Figure 4).
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In order to assess the effect of  the p85α truncation mutation in a canonically insulin-responsive cell 
type, lentiviral constructs were used to generate 3T3-L1 murine preadipocytes showing doxycycline-induc-
ible overexpression of  WT p85α or one of  two p85α mutants — the p.Tyr657X mutation studied in primary 
cells and the p.Arg649Trp mutation, which accounts for around 50% of  SHORT syndrome (Figure 4A). 
Overexpression of  mutant but not WT p85α in preadipocytes impaired differentiation of  cells to adipocytes 
on exposure to a standard adipogenic regimen (data shown for Y657X in Figure 4B) and markedly attenu-
ated insulin-induced AKT phosphorylation (Figure 4, C and D).
A dominant negative mutation in ADIPOQ. In view of  the discordance in plasma adiponectin values 
between P1 and the 3 other patients with PIK3R1 mutations and extreme insulin resistance, we reexamined 
the exome sequence of  P1 to determine whether there were any sequence variants in the ADIPOQ gene, 
encoding adiponectin. Both she and her mother, who also had severely suppressed serum adiponectin, were 
found to harbor what we believe to be a novel heterozygous missense mutation, p.Asp231Ala, within the 
globular domain of  adiponectin; this mutation was predicted to be deleterious by multiple algorithms, and 
was absent from 11,532 control exomes and genomes as well as from the 60,706 individuals in the Exome 
Aggregation Consortium (ExAC) database (33) (Figure 5, A and B).
Non-denaturing, non-reducing Western blotting of  serum from P1 revealed that expression of  all adi-
ponectin species was markedly lower compared with healthy controls and patients with genetic defects in 
the insulin receptor (Figure 5C). Instead, adiponectin levels were comparable to that of  a patient with a 
loss-of-function mutation of  AKT2. HEK293-T cells transiently transfected with mutant human ADIPOQ 
expressed and secreted lower levels of  adiponectin compared with those overexpressing the WT protein, 
as assessed by Western blotting of  cellular lysates or medium (Figure 5D). Moreover, cotransfection of  
WT and mutant adiponectin resulted in lower levels of  adiponectin secretion compared with transfection 
with WT adiponectin alone, indicating that the mutant ADIPOQ exerts a dominant negative effect over its 
WT counterpart (Figure 5D). Collectively, these data suggest that the ADIPOQ mutation causes primary 
hypoadiponectinemia in P1 and her mother. Importantly, although the proband had extreme insulin resis-
tance, her mother had a benign metabolic profile despite being obese (Table 1).
Discussion
The clinical syndromes and PIK3R1 mutations we describe are consistent with previous reports of  SHORT 
syndrome (24–26, 34). Four of  the 5 patients we describe exhibited extreme insulin resistance, while the fifth 
patient was prepubertal and male, which may explain his much milder metabolic phenotype. It has previous-
ly been shown that patients with INSR mutations, despite severe insulin resistance, do not show fatty liver, 
dyslipidemia, or suppressed plasma adiponectin, while patients from the single family described to date with 
severe insulin resistance ascribed to an AKT2 mutation exhibit all these to a severe degree (9). The insulin 
resistance subphenotype of  SHORT syndrome patients, who have a functional defect lying between INSR 
and AKT2 in the insulin signaling pathway, closely resembles that seen in INSR dysfunction. The only 
exception in this report was P1, who showed severely suppressed plasma adiponectin, which we suggest is 
attributable to the ADIPOQ p.Asp231Ala mutant identified here. Our findings suggest that normolipidemic 
severe insulin resistance without fatty liver and with preserved or elevated adiponectin may be indicative of  
proximal insulin signaling defects generally, rather than loss of  receptor function specifically.
One possible explanation for the discordance between INSR- and AKT2-associated human insulin resis-
tance subphenotypes lies in the pronounced femorogluteal lipodystrophy associated with AKT2 mutation, 
albeit only in a single family to date (9), but not with INSR mutations. This raises the possibility that AKT2 
is more important for insulin action in adipocytes than in hepatocytes, so that partial loss of  its function is 
expressed as a predominantly “lipodystrophy-like” metabolic phenotype. However SHORT syndrome, too, 
has been reported to be associated with a pattern of  lipodystrophy including loss of  femorogluteal adipose 
depots (24–26). This was not seen in P1 in this study; however, each of  the other severely insulin-resistant 
patients we describe showed generalized paucity of  subcutaneous fat. As further cases are studied, it will be 
important to assess whether SHORT syndrome does uncouple femorogluteal lipodystrophy from dyslipid-
emia and fatty liver, uniquely among lipodystrophy syndromes affecting femorogluteal depots.
Class 1A PI3K has convincingly been shown to mediate insulin’s metabolic actions; however, study of  
the specific roles of  regulatory subunits has been challenging. In contrast to the severe insulin resistance 
seen in SHORT syndrome, haploinsufficiency or complete knockout of  p85α alone (18), p85α, p55α, and 
p50α together (20, 35), p55α and p50α together (36), or p85β (19) all increase insulin sensitivity in mice. 
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Liver-specific p85α knockout also increased insulin sensitivity (37), while p85α haploinsufficiency protect-
ed mice with concomitant heterozygous knockout of  the insulin receptor and Irs1 from overt diabetes (35). 
Only when p85α and p85β were knocked out together in the liver were insulin resistance, glucose intoler-
ance, and hypolipidemia — as in the patients we describe — seen (38). One model advanced to explain this 
suggests that regulatory subunits are expressed in excess of  catalytic subunits, producing free regulatory 
subunits that can compete for phosphotyrosine binding with catalytically competent heterodimers, and 
also sequester IRS1. Reducing expression of  regulatory subunits selectively reduces the free subunits, and 
thus tightens the coupling of  insulin stimulation to PI3K activation (39). However, several lines of  evidence 
against this model have been advanced, leading to the alternative hypothesis that reduced activity of  nega-
tive regulators of  the PI3K pathway such as PTEN accounts for the increased insulin sensitivity that results 
from regulatory subunit deletion (40).
Previous signaling studies of  human SHORT-related PIK3R1 mutations in primary cells have been 
inconsistent and limited by use of  single WT control lines (24–26) and/or by use of  lymphoblastoid cells 
transformed by EBV (26), which is known to activate PI3K (41). One study reported only a baseline increase 
in downstream signaling (25), while another showed no basal difference but a very modest decrease in peak 
stimulation of  IRS1 and phosphotyrosine-associated PI3K activity (24). In Pik3r1-null murine fibroblasts 
in which WT or mutant (p.Arg649Trp) PIK3R1 was stably overexpressed, a striking reduction in IRS1-as-
sociated PI3K activity was seen in response to insulin, while, in contrast, basal phosphotyrosine-associated 
PI3K was increased, with no difference in stimulated activity (24). Our more detailed study in primary 
dermal fibroblasts using multiple control lines suggests that PI3K signaling in response to insulin is not 
impaired, but replicates the observation that association of  the mutant p85α with IRS1 in response to insu-
lin is severely reduced.
Our findings afford the opportunity to test in humans the “free regulatory subunit” hypothesis advanced 
to explain enhanced insulin sensitivity in heterozygous p85α-knockout and related mice. Truncated p85α 
was increased in the primary cells of  P1, likely due to loss of  a recently described C-terminal ubiquityla-
tion motif  (42). However, previous studies have shown that the p.Arg649Trp variant found in the other 
patients we describe does not show increased expression in primary cells, suggesting that increased regu-
latory subunit levels are not a generalized correlate of  insulin resistance in SHORT syndrome. Critically, 
we also show that the ability of  the truncated p85α to be recruited to IRS1 in response to insulin is severely 
impaired or absent in primary fibroblasts, consistent with prior studies in Pik3r1-null murine fibroblasts 
stably overexpressing the p.Arg649Trp mutant PIK3R1 (24); however, recruitment of  full-length WT p85α 
to IRS1 is normal, as are insulin-stimulated PIP3 generation and AKT phosphorylation in that cell type. 
It thus seems unlikely that competition between mutant and WT p85α explains the insulin resistance of  
SHORT syndrome. It remains possible, however, that in key insulin-responsive tissues in humans, reduc-
tion of  recruitable heterodimeric class 1A PI3K does impair insulin signaling, even though no effect could 
be discerned in dermal fibroblasts. In keeping with this, overexpression of  truncated but not WT p85α in 
3T3-L1 murine preadipocytes did attenuate insulin-induced AKT phosphorylation and impair differentia-
tion to adipocytes; however, this will require verification in insulin-responsive cells with endogenous levels 
of  mutant expression given the potential confounding effect of  perturbed stoichiometry in overexpression 
systems. Indeed, while this article was being prepared, a knockin mouse heterozygous for the Pik3r1 p.Ar-
g649Trp mutation was reported. While this exhibited insulin resistance in vivo and impaired proximal 
insulin signaling in vitro, no impairment of  preadipocyte differentiation ex vivo was reported (43).
Our finding in P1 and her mother of  a missense mutation in the ADIPOQ gene that impairs adiponectin 
secretion and acts in trans in a cell culture model to impair secretion of  coexpressed WT ADIPOQ is signifi-
cant in two respects. First, the fact that low liver fat, normal lipid profile, and nearly undetectable hepatic de 
novo lipogenesis were still seen in P1 despite concomitant genetic suppression of  adiponectin argues that 
the apparent protection from these components of  the metabolic syndrome in SHORT syndrome — and 
probably by extension also in insulin receptor defects — is not accounted for by the preserved or elevated 
plasma adiponectin seen in these forms of  severe insulin resistance. Second, the normal insulin sensitivity 
of  the mother of  the proband, despite obesity and genetic suppression of  plasma adiponectin levels, sug-
gests that primary adiponectin deficiency does not lead to highly penetrant insulin resistance. This adds 
to the debate about the metabolic importance of  adiponectin in humans. Evidence from murine models 
suggests that adiponectin exerts insulin-sensitizing effects; however, human evidence is mixed and open to 
different interpretations (44). Indeed, the largest Mendelian randomization study reported failed to provide 
1 1insight.jci.org   doi:10.1172/jci.insight.88766
R E S E A R C H  A R T I C L E
evidence for a causal role of  low plasma adiponectin in insulin resistance (45). In contrast, two smaller 
Mendelian randomization studies supported a causal link (46, 47), while a recently described family with 
a different, novel missense mutation that conferred a lesser degree of  adiponectin suppression than we 
describe, did show cosegregation between suppressed adiponectin and insulin resistance (48). As increasing 
numbers of  rare ADIPOQ alleles are identified in large-scale exome sequencing studies, it will be of  value to 
identify any that suppress plasma adiponectin and to study metabolic traits in the carriers.
None of  the patients we describe had clinical or laboratory evidence of  immunodeficiency or hypogam-
maglobulinemia. These have been associated both with germline activating mutations in PIK3R1 (21, 22) 
and, in a single patient, with a germline homozygous mutation abolishing p85α expression, with preserva-
tion of  p55α and p50α (23). The lack of  immunodeficiency in SHORT syndrome argues that in B cell devel-
opment, p85α plays an essential role that cannot be complemented by p55α and p50α, and that moreover 
does not depend critically on the C-terminal SH2 domain, which we show in other cell types is critical for 
p85 recruitment to IRS1 and phosphotyrosine-containing complexes.
In summary, our findings establish that in humans, C-terminal SH2 domain mutations in PIK3R1 pro-
duce a metabolic phenocopy of  insulin receptor dysfunction, with strikingly preserved liver fat, lipid pro-
file, and plasma adiponectin despite severe insulin resistance. Unlike deficiency of  p85α, however, they 
do not produce immunodeficiency. We demonstrate that one SHORT-associated mutation studied shows 
severely reduced recruitment to IRS1 in response to insulin in skin fibroblasts, but that this does not impair 
downstream PIP3 generation or AKT phosphorylation in the same cells. In contrast, overexpression of  the 
same mutant in murine preadipocytes, as in a recently described knockin mouse model, does attenuate 
AKT phosphorylation in response to insulin stimulation. This demonstrates that the effect of  this SHORT 
syndrome PIK3R1 mutation on insulin signaling is cell type specific. Further studies will be required to 
understand fully how SHORT syndrome–associated PIK3R1 mutations produce severe insulin resistance 
in humans, and to establish whether varying degrees of  insulin resistance in different tissues are involved 
in the protection from dyslipidemia, fatty liver, and adiponectin suppression we report in this condition.
Methods
Clinical studies. Venous blood was drawn in the fasting state and plasma immediately extracted and stored 
at –20°C. For oral glucose tolerance testing, 1.75 g glucose/kg bodyweight was given after a 10-hour fast. 
Insulin, leptin, and adiponectin were assayed using previously described dissociation-enhanced lanthanide 
fluorescence immunoassays (11). Anti–insulin receptor antibodies were sought using an IP-based assay 
described previously (49). Other analytes were determined in accredited diagnostic laboratories of  referring 
hospitals. BMI-adjusted normative adiponectin and leptin data were derived from a European ancestry 
population from the MRC Ely Study cohort (11, 50). Normative data for liver triglyceride content were 
derived from the most insulin-resistant quartile of  sex- and ancestry-matched patients from the Dallas 
Heart Study for P1(28).
Body composition was measured by Lunar Prodigy DXA (GE Healthcare). Hepatic triglyceride con-
tent was assessed by proton MRS (Siemens 3T Verio scanner) (9) and quantified as the ratio of  methylene 
and combined methylene and water signals corrected for spin-spin relaxation and expressed as a weight 
percentage. De novo lipogenesis was assessed using gas chromatography/mass spectroscopy by measuring 
the incorporation of  deuterium into plasma triglycerides during administration of  deuterium-labeled water 
(5973N GC/MS system; Agilent Technologies). All protocols have been described previously (9).
Genetic studies. Exons and at least 100 bp of  exon-flanking sequences of  the INSR gene were sequenced 
using Sanger sequencing of  PCR products using the BigDye Terminator v3.1 Cycle Sequencing Kit accord-
ing to the manufacturer’s instructions (Applied Biosystems, Life Technologies) and run on ABI 3730 DNA 
Sequencers (Applied Biosystems). Sequence analysis was performed using the Mutation Surveyor software 
package v2.3 (SoftGenetics).
For exome sequencing, genomic DNA for P1 and her parents was extracted from blood leukocytes, 
prepared for capture, and sequenced as described previously (51). Sequencing was performed on the 
Illumina Genome Analyzer II (index case) or Hi-Seq 2000 platform (parents), as 54 or 75 bp paired-end 
reads, respectively, and was mapped to the genome reference sequence (NCBI build 37) (51). Variants were 
called and annotated against Ensembl build 37 (51). Raw exome sequence data from the trio are available 
from the European Genome-Phenome Archive (https://www.ebi.ac.uk/ega/home; accession numbers 
EGAN00001001257, EGAN00001001835, and EGAN00001001824).
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Exome data for P1 and her parents were merged, and variants with a high posterior probability of  
being de novo (cutoff  value 0.8) were extracted using DeNovoGear v0.5 (https://sourceforge.net/proj-
ects/denovogear/) (29). Potential compound heterozygous mutations were also extracted. Variant anno-
tation has previously been described in detail (51). Potentially causal variants identified were reconfirmed 
by Sanger sequencing. For other patients, exons and exon-intron boundaries of  PIK3R1 were sequenced 
by Sanger sequencing.
A cohort of  262 patients with severe insulin resistance, assembled as part of  a long-running study, was 
further investigated by Sanger sequencing of  the whole PIK3R1 gene, as well as PIK3R2, encoding the p85β 
subunit, and PIK3CA, encoding the p110α catalytic subunit. All primer sequences are available in Supple-
mental Table 4.
Cell culture. Generation and culture of  EBV-transformed lymphoblastoid cell lines and dermal fibroblasts 
have been described previously (52). HEK293-T cells (ATCC) were maintained in DMEM containing 25 mM 
glucose supplemented with 10% FBS, 2 mM l-glutamine, 100 U/l penicillin, and 100 μg/ml streptomycin (all 
Sigma-Aldrich). 3T3-L1 preadipocytes (ZenBio) were cultured and differentiated as previously described (52).
Plasmid constructs and stable cell line generation. A pSG5 plasmid encoding N-terminal HA-tagged WT 
human p85α (pSG5.HA.p85α) was a gift from Bart Vanhaesebroeck, University College London. A pLP-
LNCX plasmid containing N-terminal FLAG-tagged human p110α (pLP-LNCX.FLAG.p110α) was 
obtained from Addgene (53). A pCNX2 plasmid containing N-terminal FLAG-tagged human adiponectin 
coding sequence (pCNX2.FLAG.ADIPOQ) was a gift from Louis Luttrell, Medical University of  South 
Carolina, Charleston, South Carolina (54). Site-directed mutagenesis of  the p85α and adiponectin plasmids 
was performed using primers listed in Supplemental Table 5 and the Quikchange Kit (Agilent, Stratagene), 
as per the manufacturer’s guidelines, and confirmed by direct nucleotide sequencing (55).
For protein and RNA analysis in PI3K studies, HEK293-T cells were transiently transfected 1 day after 
seeding into 6-well plates with 1.25 μg/well WT or mutant pSG5.HA.p85α and 1.25 μg/well pLP-LNCX.
FLAG.p110α, or 2.5 μg/well pcDNA3.1 empty vector, using Lipofectamine LTX (Invitrogen), as per the 
manufacturer’s guidelines. For PIP3 quantification and PI3K assays, cells were seeded into 10-cm dishes 
and transfected with 10 μg plasmid. 10% pEGFP.N1 was cotransfected in all wells to assess transfection 
efficiency (60%–80%). All assays were performed 48 hours after transfection.
3T3-L1 preadipocyte cell lines inducibly expressing WT, Y657X, or R649W mutant p85α were gener-
ated by constructing doxycycline-regulated pSLIK-Hygro lentiviral vectors containing either the mutant or 
WT gene, as described previously (55). For these experiments, PIK3R1 was amplified from a cDNA library, 
then subject to site-directed mutagenesis, using protocols described above and primers listed in Supplemen-
tal Table 1. VSV-G–pseudotyped lentiviral particles were generated and used to infect 3T3-L1 preadipo-
cytes to generate stable cell lines. Inducibility of  p85α overexpression was assessed using immunoblotting 
for total p85 and quantitative real-time PCR to detect human PIK3R1.
Insulin stimulation studies. Transfected HEK293-T cells, dermal fibroblasts, or 3T3-L1 preadipocytes 
were washed once in warm PBS, then serum starved for 16 hours in DMEM supplemented with 0.5% BSA. 
Cells were stimulated for 5 minutes at 37°C with 100 nM Actrapid insulin (unless indicated otherwise). 
Cells were lysed in tyrosine kinase lysis buffer (52) or, for PI3K assays, in PI3K lysis buffer (56). To assess 
the rate of  dephosphorylation of  AKT, insulin stimulation (as above) was terminated by washing in warm 
PBS, followed incubation in fresh serum-free medium, for the specified time intervals.
Gene expression analysis. Total RNA extraction, reverse transcription, and real-time quantitative PCR 
were performed as previously described (52). Catalog numbers for inventoried primer/probe mixes are 
listed in Supplemental Table 6.
IP and Western blotting. For IP, cleared cell lysates containing 1 mg protein (for anti-phosphotyrosine IP) 
or 200 μg protein (for HA or p85 IP) were agitated with primary antibody for 3 hours, then immobilized 
onto Protein A agarose beads (Sigma-Aldrich). Immunoblotting of  50 μg denatured total cellular protein 
or 20 μl immunoprecipitate was performed as described previously (52). Sources and concentrations of  
antibodies are listed in Supplemental Table 7. All blots shown are representative examples of  at least 3 
independent experiments. Full uncut gels are included in the supplemental material.
PIP3 quantification and PI3K activity assay. For quantification of  cellular PIP3, dermal fibroblasts were 
serum starved overnight, stimulated for 10 minutes with 100 nM insulin, then lysed in 1.5 ml 1M HCl. 
Lipid extraction, derivatization, and mass spectrometric analysis have been described previously (57).
Evaluation of  ADIPOQ mutant. Human serum was diluted 10-fold in PBS, incubated with 2× SDS 
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non-reducing Laemmli buffer (Bio-Rad) for 1 hour at room temperature, centrifuged at full speed for 3 min-
utes, then subjected to SDS-PAGE on a NuPage 4-12% Bis-Tris gradient gel (Invitrogen) in MOPS buffer. 
In the cellular model, HEK293-T cells were transferred to serum-free medium 48 hours after transfection 
with 1 μg/well or 2 μg/well WT or mutant pCNX2.FLAG.ADIPOQ. Medium was collected after 24 
hours, then incubated at room temperature with nonreducing sample buffer, as above.
Adipocyte studies. Neutral lipid staining of  3T3-L1 adipocytes on day 10 post differentiation was per-
formed using Oil Red O as described previously (52).
Statistics. Graph preparation and statistical analysis were performed in GraphPad Prism 5.0. Dot plots 
display mean ± SEM unless indicated otherwise. Differences between more than 2 groups were assessed 
for statistical significance using 1-way ANOVA, followed by post-hoc Tukey testing. Where indicated, the 
Holm-Šidák method was used to correct for multiple comparisons between 2 groups. P < 0.05 was consid-
ered statistically significant.
Study approval. Human studies were approved by the UK National Health Service Research Ethics Com-
mittee and conducted in accordance with the principles of  the Declaration of  Helsinki. Participants provid-
ed written informed consent for participation in the study and inclusion of  photographs in this publication.
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